ADHD

Medication Other

motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase

motor measurement and saliva collection

Dr med Kurt von Siebenthal

Dr med Roland Kägi

Atomoxetine, Diurnal Profiles of Cortisol and α-amylase

Atomoxetine, Diurnal Profiles of Cortisol and α-amylase, Possible Biological Markers of Treatment Success

diurnal profile of saliva cortisol and saliva alpha amylase

Martin Kammerer MD PhD

Principal Investigator

Praxis für kleine und grosse Leute

Dr med Kurt von Siebenthal, Facharztpraxis für Pädiatrie, Winterthur, Switzerland

Dr med Roland Kägi, Facharztpraxis für Pädiatrie, Zurich, Switzerland

Dr med Corrado Garbazza, University of Basle, Switzerland

Prof Vivette Glover, Imperial College London, UK

Prof Alina Rodriguez, University of Lincoln, UK

Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention

Obsessive-compulsive Disorder

Depression

Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.

Medtronic Restore Advanced 37713

Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders

Feasibility Study Regarding the Implantation and Use of Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders (Either Obsessive-compulsive Disorder or Major Depression)

Change in mean Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS). Mean Y-BOCS during the first 2 years after intervention minus mean Y-BOCS during the last 2 years before intervention.

Change in Hamilton Depression Rating Scale (HAM‐D). Mean HAM-D during the first 2 years after intervention minus mean HAM-D during the last 2 years before intervention.

Change in Beck Depression Inventory (BDI). Mean BDI during the first 2 years after intervention minus mean BDI during the last 2 years before intervention.

Change in Global Assessment of Functioning (GAF). Mean GAF during the first 2 years after intervention minus mean GAF during the last 2 years before intervention.

Change in Stimulation amplitude as measured in volt. Mean stimulation amplitude during the first 2 years after intervention minus mean stimulation amplitude during the last 2 years before intervention.

Change in Stimulation frequency as measured in hertz Mean stimulation frequency during the first 2 years after intervention minus mean stimulation frequency during the last 2 years before intervention

Stimulation pulse width as measured in seconds. Mean stimulation pulse width during the first 2 years after intervention minus mean stimulation pulse width during the last 2 years before intervention.

Change in stimulation contact configuration as expressed in fraction of patients using a certain contact point as anode or cathode.
Fraction of patients using a certain contact point as cathode or anode during the first 2 years after intervention minus fraction of patients using a certain contact point as cathode or anode during the last 2 years before intervention.

Change in frequency of outpatient clinic contacts at the Psychiatry department. Frequency of outpatient clinic contacts at the Psychiatry department during the first 2 years after intervention minus frequency of outpatient clinic contacts at the Psychiatry department during the last 2 years before intervention.

Change in fraction of hospitalized days at the Psychiatry department. Fraction of hospitalized days at the Psychiatry department during the first 2 years after intervention minus fraction of hospitalized days at the Psychiatry department during the last 2 years before intervention.

Change in frequency of outpatient clinic contacts at the Neurosurgery department.
Frequency of outpatient clinic contacts at the Neurosurgery department during the first 2 years after intervention minus frequency of outpatient clinic contacts at the Neurosurgery department during the last 2 years before intervention.

Change in fraction of hospitalized days at the Neurosurgery department. Fraction of hospitalized days at the Neurosurgery department during the first 2 years after intervention minus fraction of hospitalized days at the Neurosurgery department during the last 2 years before intervention.

Change in frequency of neurosurgical procedures related to the DBS system. Frequency of neurosurgical procedures related to the DBS system after intervention minus frequency of neurosurgical procedures related to the DBS system before intervention.

amylase/seizures

Atomoxetine, Diurnal Profiles of Cortisol and α-amylase

Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen